Larazotide
Also known as: AT-1001, INN-202, Larazotide acetate
Source Larazotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Larazotide (also known as AT‑1001 or larazotide acetate) is an investigational oral drug that blocks the action of zonulin, a protein that regulates tight‑junction permeability in the intestinal lining. By limiting zonulin‑mediated opening of tight junctions, larazotide aims to reduce the passage of gluten‑derived peptides that trigger immune activation in celiac disease. The compound is currently being studied mainly as an adjunct to a gluten‑free diet, with most clinical data derived from randomized trials in adults with celiac disease undergoing controlled gluten exposure.
Mechanism of Action
Larazotide acts as a zonulin antagonist. Zonulin normally binds to its receptor on intestinal epithelial cells, triggering a signaling cascade that disassembles the protein complexes forming tight junctions, thereby increasing paracellular permeability. By competitively inhibiting zonulin binding, larazotide stabilises tight‑junction architecture, limiting the leak of luminal antigens such as gliadin peptides into the lamina propria. This reduced antigen translocation is intended to blunt the downstream immune response that drives celiac‑related inflammation.
What the Research Shows
A 2021 review highlighted the broad role of zonulin in acute and chronic inflammatory conditions and suggested larazotide could be a therapeutic option across multiple diseases, although most evidence remains pre‑clinical. The most robust clinical data come from a 2022 systematic review and meta‑analysis of four randomized controlled trials involving 626 participants with celiac disease. Those trials showed that, during gluten challenge, larazotide improved total gastrointestinal symptom scores and celiac‑specific symptom scores compared with placebo, and it reduced gluten‑related diarrhea. However, the same analysis found no significant change in the lactulose‑to‑mannitol permeability ratio, and benefits were not observed in patients already on a strict gluten‑free diet. Additional reviews note that while larazotide has reached phase II/III testing, outcomes have been inconsistent and further studies are needed to confirm efficacy and explore use in other inflammatory disorders.
Reported Benefits
Evidence from randomized trials indicates that larazotide can lessen gastrointestinal symptoms—particularly abdominal discomfort and diarrhea—when patients with celiac disease are exposed to small amounts of gluten. The drug appears to be well tolerated, with a safety profile comparable to placebo aside from a lower incidence of gluten‑induced diarrhea. These findings suggest a potential role for larazotide as an adjunct to a gluten‑free diet, helping to mitigate accidental gluten exposure.
Limitations of the Evidence
The therapeutic effect of larazotide has been demonstrated primarily in short‑term gluten‑challenge settings; it did not improve symptoms in patients adhering to a strict gluten‑free diet. Biomarker data (lactulose‑mannitol ratio) did not show a significant reduction in intestinal permeability. The total number of trials is limited, and study populations are relatively small, leaving uncertainties about long‑term efficacy, optimal dosing, and benefits in pediatric or diverse adult cohorts. Evidence for use in other inflammatory diseases remains pre‑clinical or anecdotal.
Safety Considerations
Across the available trials, larazotide was generally well tolerated. The incidence of adverse events was similar to placebo, with the notable exception of fewer episodes of gluten‑related diarrhea in the larazotide group. No serious safety signals or organ‑specific toxicities were reported in the published studies. Nevertheless, comprehensive safety data, especially for long‑term use and in children, remain limited and warrant further investigation.
How It Is Administered
Larazotide is administered orally as an acetate formulation. In clinical studies, it has been given as a tablet taken before meals to coincide with potential gluten exposure. The exact dosing regimen varies between trials and has not been standardized for routine clinical use.
Routes of Administration
Goals & Uses
- Adjunct to gluten-free diet in celiac diseaseDisease ManagementModerate
- Reduce gastrointestinal symptoms in celiac diseaseSymptom ManagementModerate
- Non‑celiac gluten sensitivityGastrointestinalLow
- Treatment of type 1 diabetes (experimental)Autoimmune DiseaseLow
- Attenuation of gluten-induced immune activationImmunomodulationLow
- Reduce intestinal permeability in celiac diseaseGastrointestinal Barrier FunctionModerate
- Celiac diseaseAutoimmune GastrointestinalModerate
Contraindications
- Known hypersensitivity to larazotide or any excipientAllergyHigh
- Known hypersensitivity to larazotide or any excipientsAllergyModerate
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Upper respiratory tract infectionInfectiousUncommon
- DiarrheaGastrointestinalUncommonLoose or frequent stools
- Abdominal painGastrointestinalCommonPain or discomfort in the abdomen
Drug Interactions
- None reportedLow
- Gluten-containing medicationsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Children < 12 yearsPediatricRelative
- Patients with severe renal or hepatic impairmentOrgan ImpairmentRelative
- Pregnant or breastfeeding womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalUnder clinical investigation
- United StatesInvestigationalPhase III trials for celiac disease
- United KingdomInvestigationalSame as EU
Completed Phase II trials; Phase III ongoing as of 2024; not approved in any jurisdiction.
Evidence & Sources
- Journal ArticleModerateTroisi J, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighHoilat GJ, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateDamianos JA, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateYoosuf S, Makharia GK2019-01-01T00:00:00.000000Z
- Journal ArticleModerateFreeman HJ2015-01-01T00:00:00.000000Z
- Journal ArticleModerateDipasquale V, Romano C2025-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is larazotide being studied for?
Larazotide is primarily investigated as an adjunct therapy for celiac disease, aiming to reduce symptoms caused by accidental gluten exposure by tightening intestinal tight junctions.
How does larazotide differ from a gluten‑free diet?
A gluten‑free diet removes gluten from the diet, whereas larazotide does not eliminate gluten but attempts to prevent gluten peptides from crossing the intestinal barrier, potentially lessening the impact of inadvertent gluten ingestion.
Is larazotide approved for any medical use?
No. Larazotide remains an investigational compound and has not received regulatory approval for any indication as of the latest published research.
What are the most common side effects?
Clinical trials reported adverse events similar to placebo, with the main difference being a lower rate of gluten‑related diarrhea in the larazotide group; no serious safety concerns have emerged so far.
Can children with celiac disease use larazotide?
Pediatric data are limited. While some reviews mention larazotide in the context of pediatric gastroenterology, definitive efficacy and safety information for children have not yet been established.
What is Larazotide?
Larazotide (also known as AT‑1001 or larazotide acetate) is an investigational oral drug that blocks the action of zonulin, a protein that regulates tight‑junction permeability in the intestinal lining. By limiting zonulin‑mediated opening of tight junctions, larazotide aims to reduce the passage of gluten‑derived peptides that trigger immune activation in celiac disease. The compound is currently being studied mainly as an adjunct to a gluten‑free diet, with most clinical data derived from randomized trials in adults with celiac disease undergoing controlled gluten exposure.
What is Larazotide used for?
Larazotide is educationally associated with: Adjunct to gluten-free diet in celiac disease, Reduce gastrointestinal symptoms in celiac disease, Non‑celiac gluten sensitivity, Treatment of type 1 diabetes (experimental), Attenuation of gluten-induced immune activation, Reduce intestinal permeability in celiac disease, Celiac disease. Educational only — not medical advice.
How is Larazotide administered?
Recorded routes of administration: Oral.
What are the potential side effects of Larazotide?
Reported adverse effects include: Headache, Nausea, Upper respiratory tract infection, Diarrhea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Larazotide?
Recorded contraindications: Known hypersensitivity to larazotide or any excipient, Known hypersensitivity to larazotide or any excipients. Consult a qualified clinician before use.